NEJM 3-Year SURMOUNT-1 Study: Once-Weekly Tirzepatide (Zepbound & Mounjaro) Cuts Progression From Prediabetes to Type 2 Diabetes by 94%.

When the original 72-week SURMOUNT-1 obesity trial was published in the New England Journal of Medicine in 2022, 1,032 of the 2,539 enrolled adults already had prediabetes at baseline (defined by American Diabetes Association criteria: HbA1c between 5.7% and 6.4%, fasting plasma glucose 100–125 mg/dL, or 2-hour oral glucose tolerance test 140–199 mg/dL) ^[1][2][7]. Because prediabetes progresses to overt Type 2 diabetes over years rather than months, the trial protocol kept all 1,032 prediabetic participants in a double-blind randomized assignment for a full 176 weeks (nearly 3.4 years) ^[1].

At Week 176, the separation between the two groups was dramatic: in the placebo group (who received structured 500 kcal/day deficit diet counseling and 150 minutes/week of physical activity coaching), 34 out of 270 people (12.6%) developed clinical Type 2 diabetes. Across the three Tirzepatide dose groups combined, only 9 out of 762 people (1.2%) progressed to Type 2 diabetes (Hazard Ratio 0.06, 95% CI 0.03–0.13, p < 0.001) ^[1].

In medical journalism, headlines almost always quote Relative Risk Reduction (RRR) because "94% cut" sounds as if 94 out of 100 people would have gotten diabetes without the drug. In reality, prediabetes converts to Type 2 diabetes at a rate of roughly 4% to 6% per year—so over 3.3 years in the placebo + lifestyle arm, 12.6% of participants crossed the diagnostic line into Type 2 diabetes (HbA1c ≥ 6.5%) while 87.4% did not ^[1][7].

When you subtract the 1.2% event rate on Tirzepatide from the 12.6% event rate on placebo, the Absolute Risk Reduction (ARR) is 11.4 percentage points. Dividing 100 by 11.4 gives a Number Needed to Treat (NNT) of 8.8 (rounded to 9). For comparison, statins for primary heart-attack prevention over 5 years typically carry an NNT of 50 to 80, and intensive lifestyle coaching in the landmark NIH Diabetes Prevention Program (DPP) carried an NNT of 7 over 3 years ^[1][4].

After you eat a meal, your gut lining secretes two primary incretin hormones to warn your pancreas that glucose is arriving: GLP-1 (from L-cells in the lower intestine) and GIP (from K-cells in the upper duodenum). In healthy humans, GIP is actually responsible for roughly two-thirds of the post-meal incretin insulin response ^[1][2].

While GLP-1 receptor agonists (like Semaglutide in Ozempic and Wegovy) work primarily by slowing stomach emptying, quieting food noise in the brain’s hypothalamus, and stimulating glucose-dependent insulin release, GIP receptors are densely expressed on white fat cells (adipocytes). Activating GIP receptors improves blood flow and lipid storage capacity inside healthy subcutaneous fat, preventing toxic free fatty acids from spilling over into your liver and pancreas ("ectopic lipotoxicity") ^[1][2]. In SURMOUNT-1 statistical mediation modeling, 61% of the diabetes prevention came from weight loss, while 39% came from direct GIP/GLP-1 receptor effects on beta-cell insulin secretion independent of weight ^[1].

One of the most practical findings buried inside the NEJM tables is the dose-response split between weight loss and blood sugar normalization. For total body weight at Week 176, there was a clear step-up from 5 mg (-12.3% weight loss) to 10 mg (-18.7%) and 15 mg (-19.7%) ^[1].

However, for the glycemic endpoint—reverting prediabetes back to a normal HbA1c below 5.7%—89.9% of patients on the entry 5 mg maintenance dose succeeded, compared to 92.6% on 10 mg and 93.5% on 15 mg ^[1]. That means if your primary clinical goal is protecting your pancreas from progressing to Type 2 diabetes while minimizing nausea, constipation, and monthly prescription cost, staying at the 5 mg or 10 mg maintenance dose captures over 95% of the glycemic protection ^[1][5].

To test whether 3.3 years of incretin therapy permanently "reset" patients’ metabolic set-point, the investigators stopped all study injections at Week 176 and followed participants off-drug for 17 weeks (4 months) through Week 193 ^[1].

Within just 17 weeks of stopping Tirzepatide, average weight loss in the 15 mg arm eroded from -19.7% back to -12.6% (a regain of roughly 7 percentage points of body weight in 4 months), fasting insulin and HbA1c climbed, and 9 additional Tirzepatide-group participants crossed the threshold into Type 2 diabetes ^[1]. While the cumulative 193-week diabetes rate remained 88% lower than placebo (2.4% vs. 13.7%, HR 0.12), the washout curves prove that stopping a GLP-1/GIP agonist without a structured muscle-preservation and nutritional off-ramp triggers swift hormonal hunger rebound ^[1][3][6].

Whenever humans lose 15% to 20% of their body weight—whether through bariatric surgery, strict caloric restriction, or incretin pharmacotherapy—approximately one-quarter of the lost weight comes from lean body mass (skeletal muscle, organ tissue, and intracellular water) while three-quarters comes from adipose fat tissue ^[2][6].

Why does skeletal muscle matter so much for someone with prediabetes? Because skeletal muscle is your body’s largest glucose sink, responsible for clearing up to 80% of post-meal blood sugar via insulin-stimulated and contraction-stimulated GLUT4 transporters ^[6][7]. If you lose 12 lbs of skeletal muscle while on Tirzepatide and then stop the medication, your resting metabolic rate and muscle glucose disposal capacity are lower than when you started—accelerating blood sugar rebound ^[1][6].

Over 176 weeks of continuous exposure, no new or unexpected safety signals emerged beyond the established FDA label for Zepbound and Mounjaro ^[1][5]. Nausea, diarrhea, dyspepsia, and constipation clustered heavily during the first 20 weeks while doses were stepped up in 2.5 mg increments every 4 weeks; after reaching a stable maintenance dose, monthly GI event rates fell below 5% ^[1][2].

Treatment discontinuation due to adverse events over 3.3 years was 7.0% (5 mg), 9.6% (10 mg), and 12.3% (15 mg), compared to 5.9% on placebo ^[1]. Because rapid mobilization of cholesterol from shrinking fat tissue increases bile saturation, acute gallbladder disease (cholelithiasis and cholecystitis) occurred roughly 2.5 to 3 times more frequently on Tirzepatide than placebo, and pancreatitis remained rare (< 0.5% across arms) ^[1][5].

In rats administered Tirzepatide at clinically relevant exposures for two years, there was a dose-dependent increase in thyroid C-cell adenomas and carcinomas ^[5]. While large human cohort analyses have not confirmed a clear causal increase in human medullary thyroid cancer to date, the FDA mandates a strict contraindication for any patient with personal or family history of MTC or MEN 2 ^[5].

Additionally, Tirzepatide slows gastric emptying, which has two major clinical implications: (1) it can reduce the absorption of oral birth-control pills for 4 weeks after initiation and after each dose increase (requiring backup non-oral contraception), and (2) anesthesiologists require pausing weekly GLP-1/GIP injections prior to elective surgery under general anesthesia or deep sedation to prevent pulmonary aspiration of retained stomach contents ^[5].

In the landmark NIH Diabetes Prevention Program (DPP, N = 3,234 followed for 2.8 years), intensive lifestyle coaching (losing 7% of body weight and walking 150 minutes/week) cut progression from prediabetes to Type 2 diabetes by 58%, while generic Metformin (850 mg twice daily) cut risk by 31% overall—and by 53% in younger adults under age 45 with a BMI ≥ 35 kg/m² ^[4].

Tirzepatide’s 94% risk reduction in SURMOUNT-1 is substantially stronger because it drives 15%–20% total weight loss (nearly triple the DPP lifestyle weight loss) ^[1][4]. However, for a patient with mild prediabetes (HbA1c 5.8%–6.0%) and a BMI under 30, starting with post-meal walking, resistance training, and $4/month Extended-Release Metformin ER remains far more cost-effective and free of off-drug rebound risk ^[4][7][8].

Every clinical trial audit must examine funding and trial design limitations. First, Eli Lilly funded the trial, employed several co-authors, and performed the statistical analyses—though the trial was double-blinded, registered prospectively on ClinicalTrials.gov (NCT04184622), and peer-reviewed by the New England Journal of Medicine ^[1].

Second, SURMOUNT-1 only enrolled prediabetic adults who also had obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with weight-related comorbidities; we cannot extrapolate these results to normal-weight adults with prediabetes ("lean prediabetes") ^[1]. Third, the control arm received placebo + lifestyle rather than active generic Metformin ER, so we lack a direct head-to-head RCT comparing Tirzepatide against Metformin or Tirzepatide + Metformin combination therapy in prediabetes ^[1][4].

Because Medicare Part D is statutorily barred from covering medications prescribed solely for weight loss, Medicare only covers Tirzepatide when a patient has an established diagnosis of Type 2 Diabetes (Mounjaro), cardiovascular risk indication, or qualifying FDA-approved comorbidity such as moderate-to-severe obstructive sleep apnea with obesity (Zepbound) ^[5][7].

For commercial insurance plans that cover Zepbound, an adult with prediabetes and a BMI ≥ 27 (since prediabetes counts as a weight-related comorbidity alongside hypertension or dyslipidemia) often meets prior-authorization criteria. For cash-pay patients without coverage, Eli Lilly’s direct single-dose vial program (LillyDirect) prices 2.5 mg and 5 mg weekly doses at $399 to $499/month, compared to the ~$1,060 retail auto-injector list price ^[5].

Not every person with prediabetes has the same 3-year risk of developing Type 2 diabetes. In clinical cohorts, someone with an HbA1c of 5.7% and normal fasting triglycerides has a < 2% annual conversion rate, whereas someone with an HbA1c of 6.3%, fasting glucose of 120 mg/dL, and elevated waist circumference faces a 10%–15% annual conversion risk ^[4][7].

Bring these 4 questions to your appointment: (1) "Given my exact HbA1c (5.7%–6.4%) and fasting glucose, what is my realistic 3-year risk of progressing to Type 2 diabetes?" (2) "Should we start with a 90-day lifestyle + Extended-Release Metformin ER protocol first, or does my BMI/sleep apnea/cardiovascular risk warrant a dual GIP/GLP-1 agonist now?" (3) "If we use Tirzepatide, can we stay at the 5 mg maintenance dose that achieved 89.9% normoglycemia in SURMOUNT-1?" and (4) "How will we monitor my protein intake and skeletal muscle mass so I don’t lose muscle?" ^[1][4][6][7].